Dr. Jane Tiller

And then they were referred into the public health system for the follow-up care and care coordination and surveillance and things like that.

But also because we have a public health care system in Australia, people didn't have that cost.

barrier of continuing on with preventive healthcare.

And some studies that have been conducted by healthcare providers in places like the US have found a really rapid drop-off of follow-up.

And in some cases, that's because people have to pay for it themselves.

They're out-of-pocket costs and they don't get public healthcare for that surveillance and preventive care, which is a real feature.

Yeah.

You're absolutely right.

And I think the question was around the people who engaged with follow-up.

There are real concerns around access to that healthcare downstream and the ability of our system to scale up sufficiently.

As we said before, if we tested the whole population, 2% might not seem like a lot, but that's a lot of thousands of people who are then adding to waiting lists downstream to

But the concept that they can access that care, they can access specialist genetic services without cost to them, there are wait times.

But the deterrence of having out-of-pocket costs to get that isn't making people kind of say, well, I'm not going to pursue this further.

We absolutely need to work on scale and efficiency and downstream care because that is not up to scratch and will need to be worked on.

You've been listening to an ABC podcast.

Discover more great ABC podcasts live radio and exclusives on the ABC Listen app.